TY - JOUR
T1 - The characterization of anti-T. cruzi activity relationships between ferrocenyl, cyrhetrenyl complexes and ROS release
AU - Echeverría, César
AU - Romero, Valentina
AU - Arancibia, Rodrigo
AU - Klahn, Hugo
AU - Montorfano, Ignacio
AU - Armisen, Ricardo
AU - Borgna, Vincenzo
AU - Simon, Felipe
AU - Ramirez-Tagle, Rodrigo
N1 - Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Trypanosoma cruzi (T. cruzi) is the parasite that causes Chagas disease. Nifurtimox is the most used drug against the T. cruzi, this drug increases intermediaries nitro group, being mainly responsible for the high toxicity component, for this reason it is important to study new organic compounds and thus improve therapeutic strategies against Chagas disease. The electronic effects of ferrocenyl and cyrhetrenyl fragments were investigated by DFT calculation. A close correlation was found between HOMO–LUMO gap of nitro radical NO2 − with the experimental reduction potential found for nitro group and IC50 of two forms the T. cruzi (epimastigote and trypomastigote). The IC50 on human hepatoma cells is higher for both compounds compared to IC50 demonstrated in the two forms the T. cruzi, and additionally show reactive oxygen species release. The information obtained in this paper could generate two new drugs with anti-T. cruzi activity, but additional studies are needed.
AB - Trypanosoma cruzi (T. cruzi) is the parasite that causes Chagas disease. Nifurtimox is the most used drug against the T. cruzi, this drug increases intermediaries nitro group, being mainly responsible for the high toxicity component, for this reason it is important to study new organic compounds and thus improve therapeutic strategies against Chagas disease. The electronic effects of ferrocenyl and cyrhetrenyl fragments were investigated by DFT calculation. A close correlation was found between HOMO–LUMO gap of nitro radical NO2 − with the experimental reduction potential found for nitro group and IC50 of two forms the T. cruzi (epimastigote and trypomastigote). The IC50 on human hepatoma cells is higher for both compounds compared to IC50 demonstrated in the two forms the T. cruzi, and additionally show reactive oxygen species release. The information obtained in this paper could generate two new drugs with anti-T. cruzi activity, but additional studies are needed.
KW - Anti-chagasic
KW - DFT
KW - Reactive oxygen species
KW - Trypanosoma cruzi
UR - http://www.scopus.com/inward/record.url?scp=84979708977&partnerID=8YFLogxK
U2 - 10.1007/s10534-016-9953-1
DO - 10.1007/s10534-016-9953-1
M3 - Article
C2 - 27460450
AN - SCOPUS:84979708977
SN - 0966-0844
VL - 29
SP - 743
EP - 749
JO - BioMetals
JF - BioMetals
IS - 4
ER -
